^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
OncoDNA

i
Other names: OncoDNA | OncoDNA S.A.
Related tests:
Evidence

News

5ms
OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer (OncoDNA Press Release)
"OncoDNA...announced its support to the extension of the AURORA program, which aims to include 252 more patients. The extension will specifically focus on patients with Triple Negative Breast Cancer (TNBC), Invasive Lobular Carcinoma (ILC) and those with late relapses beyond 10 years of initial breast cancer diagnosis."
Licensing / partnership
6ms
C2i Genomics and OncoDNA begin molecular residual disease testing across Europe (OncoDNA Press Release)
"OncoDNA...announced the next stage in its partnership with C2i Genomics...The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test."
Licensing / partnership
|
C2inform test
1year
OncoDNA and its partners are proud to be selected by the oncNGS Consortium to develop a solution for the liquid biopsies (OncoDNA Press Release)
"OncoDNA...announced its participation in the oncNGS tender. Together with IQVIA, we are challenged by the ONCNGS CONSORTIUM to come up with a solution for analysis in liquid biopsies which should represent the ‘best NGS test, for all solid and lymphoid tumors’."
Clinical
over1year
Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients (OncoDNA Press Release)
"OncoDNA...and ELI LILLY ITALIA...are proud to announce their partnership to facilitate access to biomarker testing and support the selection of the best therapy for thyroid cancer patients in italy...The partnership between Lilly and OncoDNA provides next-generation sequencing (NGS) molecular testing for thyroid cancer on tumor tissue biopsy to individuate treatable cancer biomarkers, by the identification of several gene alterations leading to potentially eligible patients for targeted therapies."
Licensing / partnership
over1year
Berkshire and Surrey Pathology Services & ONCODNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK (OncoDNA Press Release)
"...this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP for the purpose of routine next generation sequencing."
Licensing / partnership
|
OncoDEEP
over1year
OncoDNA announces the operational launch of its OncoDEEP® kit for comprehensive genomic profiling of solid tumors (OncoDNA Press Release)
"ONCODNA...ANNOUNCED THE OFFICIAL LAUNCH OF THE ONCODEEP KIT DURING THE ESMO (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) CONGRESS IN PARIS, FRANCE. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION TO ENABLE LABORATORIES WITH NGS CAPABILITIES TO SUPPORT ONCOLOGISTS IN FINDING THE MOST EFFECTIVE AND PERSONALIZED TREATMENTS FOR THEIR CANCER PATIENTS."
Launch Europe
|
OncoDEEP
2years
OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany (OncoDNA Press Release)
"OncoDNA...announced today a partnership with Synlab...integrating OncoDEEP in their portfolio, Synlab laboratories in Germany will perform comprehensive testing of solid tumors and deliver decision support for oncologists. The technology transfer is ongoing, with the objective of processing the first patient samples early Q2."
Licensing / partnership
|
OncoDEEP
2years
OncoDNA launches OncoDEEP® kit for comprehensive biomarker testing of solid tumors (OncoDNA Press Release)
"OncoDNA...announced today the launch of the OncoDEEP kit. The kit offers a complete workflow solution which enables laboratories with NGS capabilities to perform comprehensive biomarker testing, provide powerful data analysis and support oncologists in the most effective and personalized treatments for their cancer patients. The OncoDEEP kit integrates both reagents and quality control standards for the sequencing of over 600 cancer biomarkers. the offer will come in combination with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. OncoDEEP kit is available for early access and will be commercially available by the end of Q2 2022."
Launch
|
OncoDEEP
over2years
C2i Genomics partners with OncoDNA to bring AI-powered liquid biopsy for cancer diagnostics across Europe (OncoDNA Press Release)
"C2i Genomics...announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects."
Licensing / partnership
over2years
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology (OncoDNA Press Release)
"OncoDNA...and Bergonié Institute...announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 participating sites across the French Aquitaine region to be offered OncoDEEP® and OncoFOLLOW™ biomarker tests."
New trial
|
OncoDEEP • OncoFOLLOW